Korea AstraZeneca announced on the 30th that it has signed a memorandum of understanding (MOU) with AI-based software startup Oncosoft to improve the diagnostic and evaluation environment for patients with neurofibromatosis type 1 (NF1).
NF1 is a rare genetic disorder that can cause various symptoms throughout the body, including light brown spots (café-au-lait spots), freckles, and plexiform neurofibromas.
Currently, to receive reimbursement for the treatment of NF1 with plexiform neurofibromas, the change in the volume of the target lesion must be assessed every six months via Volumetric MRI (V.MRI). However, this process is significantly more time-consuming than conventional reading, creating challenges in the clinical setting.
Through this agreement, the two companies will collaborate to reduce the burden of V.MRI reading and expand treatment opportunities for patients by utilizing an AI-based analysis solution.
